See Cancer In Real Time

The Stryker 1788 Platform is now cleared for use with CYTALUX. READ MORE >

CYTALUX® (pafolacianine) injection is the only targeted molecular imaging agent that illuminates ovarian and lung cancer intraoperatively.

CYTALUX in Action

See how CYTALUX enhances surgeons’ ability to visualize lung and ovarian lesions.

See CYTALUX in action

CYTALUX is indicated as an adjunct for intraoperative identification of malignant lesions in adult patients with ovarian cancer and malignant and non-malignant pulmonary lesions in adult patients with known or suspected cancer in the lung.

In clinical trials, CYTALUX detected additional ovarian and lung cancer
that wouldn’t have been detected otherwise.

* Women highly suspicious for or with confirmed ovarian cancer who underwent both normal and fluorescent light evaluation (Intent-to-Image set); N=134, 95% CI [19.6, 35.2]

Speak with a representative
about CYTALUX and how to bring this technology to your OR.